Ewing sarcoma
An EWSR1 fusion-driven sarcoma of children and young adults; relapsed disease has few options.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 7 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for Ewing sarcoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 9 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Literature | Pathways | genetic literature | Clinical |
|---|---|---|---|---|---|---|---|
| STAG2 STAG2 cohesin complex component | 0.52 | – | 0.82 | ||||
| TP53Peds RMTL tumor protein p53 | 0.51 | – | 0.80 | ||||
| FLI1 Fli-1 proto-oncogene, ETS transcription factor | 0.42 | – | – | ||||
| NF1 neurofibromin 1 | 0.42 | 0.55 | 0.55 | ||||
| EWSR1 EWS RNA binding protein 1 | 0.41 | 0.01 | 0.18 | ||||
| TOP2A DNA topoisomerase II alpha | 0.41 | – | – | ||||
| TUBB3 tubulin beta 3 class III | 0.40 | – | – | ||||
| TUBA1A tubulin alpha 1a | 0.40 | – | – | ||||
| TUBB tubulin beta class I | 0.40 | – | – | ||||
| TUBB4A tubulin beta 4A class IVa | 0.40 | – | – | ||||
| TUBB2B tubulin beta 2B class IIb | 0.40 | – | – | ||||
| TUBA1C tubulin alpha 1c | 0.40 | – | – | ||||
| TUBA3C tubulin alpha 3c | 0.40 | – | – | ||||
| TUBA1B tubulin alpha 1b | 0.40 | – | – | ||||
| TUBB8 tubulin beta 8 class VIII | 0.40 | – | – | ||||
| TUBB2A tubulin beta 2A class IIa | 0.40 | – | – | ||||
| TUBB4B tubulin beta 4B class IVb | 0.40 | – | – | ||||
| TUBB1 tubulin beta 1 class VI | 0.40 | – | – | ||||
| TUBA4A tubulin alpha 4a | 0.40 | – | – | ||||
| TUBB6 tubulin beta 6 class V | 0.40 | – | – | ||||
| TUBA3E tubulin alpha 3e | 0.40 | – | – | ||||
| TOP2B DNA topoisomerase II beta | 0.39 | – | – | ||||
| ERG ETS transcription factor ERG | 0.38 | – | – | ||||
| TOP1 DNA topoisomerase I | 0.38 | – | – | ||||
| ETV1 ETS variant transcription factor 1 | 0.37 | – | – | ||||
| NR4A3 nuclear receptor subfamily 4 group A member 3 | 0.37 | – | – | ||||
| EGR2 early growth response 2 | 0.33 | 0.54 | – | ||||
| IGF1RPeds RMTL insulin like growth factor 1 receptor | 0.32 | – | – | ||||
| KIZ kizuna centrosomal protein | 0.32 | 0.53 | – | ||||
| RREB1 ras responsive element binding protein 1 | 0.31 | 0.51 | – | ||||
| CIROZ ciliated left-right organizer protein containing ZP-N domains | 0.31 | 0.51 | – | ||||
| CSF3R colony stimulating factor 3 receptor | 0.29 | – | – | ||||
| NKX2-2 NK2 homeobox 2 | 0.29 | 0.44 | – | ||||
| SLC6A3 solute carrier family 6 member 3 | 0.28 | – | – | ||||
| BAP1 BRCA1 associated deubiquitinase 1 | 0.27 | 0.44 | – | ||||
| EZH2Peds RMTL enhancer of zeste 2 polycomb repressive complex 2 subunit | 0.26 | – | 0.40 | ||||
| FDPS farnesyl diphosphate synthase | 0.26 | – | – | ||||
| SRP14 signal recognition particle 14 | 0.25 | 0.41 | – | ||||
| KITPeds RMTL KIT proto-oncogene, receptor tyrosine kinase | 0.23 | – | – | ||||
| PDGFRBPeds RMTL platelet derived growth factor receptor beta | 0.23 | – | – | ||||
| RETPeds RMTL ret proto-oncogene | 0.23 | – | – | ||||
| KDR kinase insert domain receptor | 0.23 | – | – | ||||
| EPHA2Peds RMTL EPH receptor A2 | 0.23 | – | – | ||||
| FGFR1 fibroblast growth factor receptor 1 | 0.23 | – | – | ||||
| ABL1Peds RMTL ABL proto-oncogene 1, non-receptor tyrosine kinase | 0.22 | – | – | ||||
| FLT4 fms related receptor tyrosine kinase 4 | 0.22 | – | – | ||||
| FLT1 fms related receptor tyrosine kinase 1 | 0.22 | – | – | ||||
| NTRK1 neurotrophic receptor tyrosine kinase 1 | 0.22 | – | – | ||||
| TEK TEK receptor tyrosine kinase | 0.22 | – | – | ||||
| PDGFRAPeds RMTL platelet derived growth factor receptor alpha | 0.22 | – | – |
4 biomarkers in Ewing sarcoma have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Ewing Sarcoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 18 accepted items exist; the first 18 were read. This is the published evidence, not treatment advice.
- EWSR1::FLI1 Fusion level B
- EWSR1::ERG Fusion level B
- EWSR1::FLI1 e7::e6 level B
- STAG2 MUTATION level B